Home > Oncology > ASCO GU 2022 > Prostate Cancer > Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide

Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide

Presented By
Dr Axel Merseburger, Universit├Ątsklinikum Schleswig-Holstein, Germany
Conference
ASCO GU 2022
Trial
Phase 3, PRESIDE
In patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel plus prednisolone who have progressed on enzalutamide, the continuation of enzalutamide plus docetaxel led to a significant improvement of progression-free survival (PFS), results from the phase 3 PRESIDE study showed. Treatment with enzalutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of metastatic progression or death over time versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC) or non-metastatic castration-resistant prostate cancer (nmCRPC) [1,2]. The phase 3 PRESIDE trial (NCT02288247) evaluated the benefit of continuation of enzalutamide plus ADT plus docetaxel in men with mCRPC who progressed on enzalutamide plus ADT. The study enrolled chemotherapy-naïve men with mCRPC wh...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on